榮昌生物製藥（煙台）股份有限公司 章程 榮昌生物製藥（煙台）股份有限公司 2025年7月 | 第一章 | 總則 | 4 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 6 | | 第三章 | 股份 | 6 | | 第一節 | 股份發行 | 6 | | 第二節 | 股份增減和回購 | 7 | | 第三節 | 股份轉讓 | 8 | | 第四章 | 股東和股東會 | 9 | | 第一節 | 股東的一般規定 | 9 | | 第二節 | 控股股東和實際控制人 | 12 | | 第三節 | 股東會的一般規定 | 13 | | 第四節 | 股東會的召集 | 16 | | 第五節 | 股東會的提案與通知 | 17 | | 第六節 | 股東會的召開 | 19 | | 第七節 | 股東會的表決和決議 | 22 | | 第五章 | 董事和董事會 | 25 | | 第一節 | 董事的一般規定 | 25 | | 第二節 | 董事會 | 29 | | 第三節 | 獨立董事 | 34 | | 第四節 | 董事會專門委員會 | 38 | | 第六章 | 高級管理人員 | 40 | | --- | --- | ...

北京市金杜律师事务所 关于荣昌生物制药（烟台）股份有限公司 2025 年第二次 H 股类别股东大会 之法律意见书 致：荣昌生物制药（烟台）股份有限公司 北京市金杜律师事务所（以下简称本所）接受荣昌生物制药（烟台）股份有限 公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证券法》）、 《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理委员会《上 市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国境内（以下简 称中国境内，为本法律意见书之目的，不包括中国香港特别行政区、中国澳门特别 行政区和中国台湾省）现行有效的法律、行政法规、规章、规范性文件和现行有效 的公司章程的有关规定，指派律师出席了公司于 2025 年 7 月 31 日召开的 2025 年 第二次 H 股类别股东大会（以下简称"本次 H 股类别股东大会"），并就本次 H 股类别股东大会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2023 年年度股东大会审议通过的《荣昌生物制药（烟台）股份有限 公司章程》（以下简称《公司章程》）； 2. 2025 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 董事長兼執行董事 王威東先生 中國煙台 2025年7月31日 於本公告日期，董事會成員包括執行董事王威東先生、房健民博士、溫慶凱先生 及林健先生；非執行董事王荔強博士及蘇曉迪博士；及獨立非執行董事郝先經先 生、陳雲金先生及黃國濱先生。 * 僅供識別 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由榮昌生物製藥 （煙台）股份有限公司（「本公司」）作出。 茲載列本公司於上海證券交易所網站刊登公告如下，僅供參閱。 承董事會命 榮昌生物製藥（煙台）股份有限公司 北京市金杜律师事务所 关于荣昌生物制药（烟台）股份有限公司 2025 年第二次 H 股类别股东大会 之法律意见书 致：荣昌生物制药（烟台）股份有限公司 北京市金杜律师 ...

RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 2025年第二次H股類別股東大會投票表決結果 茲提述榮昌生物製藥（煙台）股份有限公司（「本公司」）日期為2025年7月15日載列 （其中包括）2025年第二次H股類別股東大會（「H股類別股東大會」）的通告的通函 （「通函」）。除非文義另有所指，否則本公告所用詞彙與通函所界定者具有相同涵 義。 董事會欣然宣佈，本公司於2025年7月31日（星期四）假座中國山東省自由貿易試 驗區煙台片區煙台開發區北京中路58號公司三期大樓6134會議室舉行H股類別股 東大會。 本公司的H股證券登記處香港中央證券登記有限公司於H股類別股東大會擔任投票 表決的監票員。兩名股東代表、北京市金杜律師事務所的兩名律師及本公司一名 監事參加監票。 承董事會命 就本公司所知 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 董事會欣然宣佈，本公司於2025年7月31日（星期四）假座中國山東省自由貿易試 驗區煙台片區煙台開發區北京中路58號公司三期大樓6134會議室舉行H股類別股 東大會。 於H股類別股東大會日期，本公司已發行股份為563,608,243 股股份，包括 355,027,004股A股及208,581,239股H股。因此，賦予股東權利以出席H股類別股 東大會並於會上就決議案投票的H股總數為208,581,239股股份。 就本公司所知、所悉及所信：(1)概無股份賦予持有人權利出席但須根據上市規則 第13.40條就H股類別股東大會上提呈的決議案放棄投贊成票；(2)並無股東須根據 上市規則規定就H股類別股東大會上提呈的決議案放棄投票；及(3)並無任何一方 於通函中表明其有意於H股 ...

Group 1 - The article provides a list of companies listed on the Hong Kong stock market along with their dividend distribution dates and shareholder meeting dates [1][4][5] - Notable companies mentioned include China Railway, Green Town China, and Budweiser APAC, which are scheduled for dividend payments [4][5] - The document outlines various companies' actions regarding capital increases and dividend distributions, indicating ongoing corporate activities in the market [4][5]

Core Viewpoint - The announcement of HRS-9821 project licensing to GlaxoSmithKline (GSK) by Heng Rui Medicine signifies a growing trend of multinational pharmaceutical companies acquiring innovative drugs from Chinese firms, reflecting a competitive landscape in the Chinese pharmaceutical market [1][5][19]. Group 1: Licensing and Financial Details - Heng Rui Medicine will receive a $500 million upfront payment from GSK, with potential milestone payments reaching up to $12 billion based on successful development, registration, and sales [2]. - The licensing agreement excludes regions such as mainland China, Hong Kong, Macau, and Taiwan, indicating a strategic focus on international markets [1]. - The deal has positively impacted Heng Rui Medicine's stock prices in both A-shares and Hong Kong stocks [4]. Group 2: Market Trends and Acquisitions - In the first half of the year, multinational pharmaceutical companies invested approximately 464.3 billion yuan ($64.5 billion) in acquiring Chinese innovative drugs, indicating a surge in interest [6][19]. - The "buy-buy-buy" strategy adopted by these companies highlights a shift towards acquiring rather than developing new drugs internally [7][20]. - Notable transactions include Pfizer's acquisition of a PD-1/VEGF bispecific antibody from 3SBio for $12.5 billion, marking a record for domestic innovative drug deals [8][10]. Group 3: Characteristics of Transactions - The average transaction amounts are substantial, with many exceeding $1 billion, and the largest deals surpassing $6 billion [15]. - Major pharmaceutical companies involved in these transactions include Pfizer, Roche, and AstraZeneca, all ranked among the top ten global pharmaceutical firms [16]. - The focus of these acquisitions is on high-tech areas such as oncology, autoimmune diseases, and metabolic disorders, showcasing the advanced nature of the Chinese pharmaceutical pipeline [17]. Group 4: Rationale Behind Acquisitions - The high risk and long development timelines associated with innovative drug development make acquisitions a more attractive option for multinational companies [20][22]. - Acquiring innovative drugs allows these companies to quickly fill gaps in their pipelines and respond to competitive pressures in the market [25][27]. - The trend of increasing external procurement from Chinese companies has risen from 10% in 2020 to 29% in 2023, indicating a growing recognition of the value of Chinese innovation [17][19]. Group 5: Advantages of Chinese Innovative Drugs - Chinese innovative drugs are perceived as high-quality and cost-effective compared to similar products in developed markets, making them appealing to multinational companies [36][40]. - The lower costs associated with drug development in China, estimated to be 20-30% of those in the U.S., further enhance the attractiveness of these assets [40]. - The increasing number of new drug approvals and ongoing research pipelines in China positions the country as a significant player in the global pharmaceutical landscape [36][38].

港股生物医药板块午后走弱，荣昌生物(09995.HK)跌超7%，君实生物(01877.HK)跌超6%，再鼎医药 (09688.HK)、复宏汉霖(02696.HK)等跟跌。 ...

Core Insights - The Chinese pharmaceutical industry is experiencing a resurgence after three years of stagnation, driven by high-value licensing deals from multinational pharmaceutical companies [1][2] - There is a significant interest from overseas investors in Chinese biopharmaceutical companies, with a notable increase in licensing agreements and IPO activities [2][8] - The trend of "licensing out" Chinese drug candidates to foreign companies is becoming more common, providing Chinese firms with milestone payments and a share of sales revenue [4][6] Group 1: Market Dynamics - As of mid-July, approximately 288 companies are waiting for IPOs in Hong Kong, many of which are biopharmaceutical firms seeking to list under the 18A rule [1][8] - The Hong Kong medical sector has seen a 54% increase this year, significantly outperforming the MSCI China Index, which rose by 17% [8] - The average price-to-earnings (PE) ratio for the sector is around 30 times, placing it in the 15th percentile of its valuation range over the past five years [8] Group 2: Investment Trends - U.S. investment banks are playing a crucial role in facilitating these licensing deals and IPOs, with cornerstone investors contributing 42% of IPO financing this year, two-thirds of which comes from overseas [1][12] - The trend of U.S. pharmaceutical companies seeking to lower costs through partnerships with Chinese firms is expected to continue, especially in light of U.S. drug pricing policies [2][6] Group 3: Licensing Agreements - The number of licensing transactions from China has increased significantly, with 35 deals in 2023 and projected to reach 43 in 2024, alongside a total upfront payment of $2.957 billion in 2023 [3][6] - Notable licensing agreements include Akeso's ivonescimab, which was licensed to Summit Therapeutics for a total value of $5 billion, marking one of the largest overseas licensing deals in Chinese biopharmaceutical history [7][6] Group 4: Future Outlook - Chinese biopharmaceutical companies are increasingly able to produce globally recognized clinical data, particularly in competitive fields like oncology and immunology [2][6] - The shift from merely selling drug pipelines to achieving global commercialization is essential for the future growth of Chinese pharmaceutical companies [13][15] - There is a need for Chinese firms to enhance their innovation capabilities and international execution to compete effectively on a global scale [14][15]

Core Insights - The report maintains a positive outlook on small molecule drug conjugates (SMDCs) and related companies, highlighting their potential in cancer treatment due to their ability to enhance efficacy while reducing toxicity [1][5][17] - The report emphasizes the clinical advantages of SMDCs, including better tumor penetration, reduced toxicity to normal cells, and easier control over synthesis and costs compared to antibody-drug conjugates (ADCs) [5][11][12] - The report identifies domestic biopharmaceutical companies, particularly Affinivax, as leaders in the SMDC space, showcasing significant advancements in innovative cancer drug development [5][12][17] Industry Overview - The pharmaceutical and biotechnology sector has shown a relative price-to-earnings (P/E) ratio of 51.14 as of July 25, 2025, which is significantly higher than its historical low of 24.38, indicating a premium valuation compared to the broader market [19] - The report notes that the healthcare sector's valuation is 279% higher than the Shanghai Composite Index, reflecting strong investor interest and confidence in the industry [19] - Recent market performance indicates a 1.90% increase in the pharmaceutical and biotechnology sector from July 21 to July 25, 2025, ranking it 16th among 27 sub-industries [26][29] Company Focus - The report suggests monitoring companies involved in the SMDC space, including Affinivax, and those collaborating with them, such as Innovent Biologics and others, which are expected to benefit from the growing interest in innovative cancer therapies [5][17][18] - Specific companies highlighted for their innovative drug development capabilities include Innovent Biologics, Shunyi Pharmaceutical, and others, which are positioned to capitalize on the advancements in SMDC technology [5][18]